Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Nine-month interim report (Q3) 2024 (unaudited) Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by...
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) ALK (ALKB:DC / OMX: ALK B) today announced that it has entered...
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024 ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine...
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014...
Six-month interim report (Q2) 2024 Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a...
ALK upgrades its full-year revenue and earnings outlook ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance...
Invitation to the presentation of ALK’s results for the first six months (Q2) 2024 on Friday 23 August 2024 ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first six months...
ALK upgrades its full-year revenue and earnings outlook ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than...
ALK provides update on regulatory process for the house dust mite allergy tablet in China ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic...
ALK launches new growth strategy and 2028 financial ambitions ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
